TPW 6.17 Clinicopathological Characteristics and Survival Outcomes of Gastric Hepatoid Adenocarcinoma: A Multicenter Retrospective Study

Clicks: 1
ID: 323966
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #294 of 432 articles by views in the british journal of surgery

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objective To investigate the clinicopathological characteristics, immunohistochemical features, treatment patterns, and survival outcomes of patients with gastric hepatoid adenocarcinoma (HAS). Methods Clinicopathological data of 37 patients diagnosed with HAS between July 2008 and February 2023 were retrospectively collected from seven medical centers. Demographic characteristics, clinical presentations, pathological and immunohistochemical findings, treatment strategies, and prognostic outcomes were analyzed. Results Among the 37 patients, 30 were male and 7 were female, with a mean age of 61.95 years. Abdominal pain was the most common initial symptom. Elevated serum alpha-fetoprotein levels were observed in 21 patients. Thirty patients underwent surgical treatment, including 27 radical and 3 palliative procedures. Tumor stages I, II, III, and IV accounted for 1, 6, 18, and 12 cases, respectively. Immunohistochemical positivity rates were 51.35% for GPC-3, 32.43% for HepPar-1, 16.22% for SALL4, and 13.51% for CDX-2. Five patients who received six or more cycles of postoperative adjuvant chemotherapy achieved favourable survival outcomes, with the longest survival reaching 54 months. Conclusions HAS is a rare and aggressive subtype of gastric cancer, predominantly affecting elderly men and often presenting at an advanced stage. Radical surgery remains the cornerstone of treatment, and postoperative adjuvant chemotherapy with more than six cycles may contribute to improved long-term survival.
Reference Key
openalex_W7172513321 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Fanghui Ding, Quanlin Guan, Fanghong Wang, Jianling Zhang, xun li
Journal the british journal of surgery
Year 2026
DOI
10.1093/bjs/znag087.370
URL
https://doi.org/10.1093/bjs/znag087.370
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.